glp-1 and addiction IUPHAR review – Glucagon-like peptide-1 (GLP-1) substance use disorders: An emerging pharmacotherapeutic target Hype Or Hope? Latest Research

Learn about their unique characteristics, benefits, side effec...

Glucagon-like peptide-1 (GLP-1) receptor agonists were touted as breakthrough drugsin 2023 and their popularity has soared since. More than 4 million items of tirzepatide and semaglutide were dispensed on the NHS in England in 2025/20261, while around2.5 million people each monthaccessed GLP-1s privately at the end of 2025, according to James Kingsland, chair of []

analysis of treatment plans, including compounded GLP-1s, customers taking a compounded GLP-1 reported losing an average of 20.9 pounds or 10.3% of initial body weight, within six months, while reporting a low rate of side effects

Second, over over-half of health plans focus on member communications, informing health plan enrollees on alternative options to the expensive drugs

However, the cost of sitagliptin and the need for more data may restrict its use

FRIDAY, Aug